Consolidated Statements of Redeemable Convertible Preferred Shares and Shareholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Total LianBio Shareholders’ Equity	Ordinary Shares	Additional Paid in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Non- Controlling Interest
Beginning balance (in shares) at Dec. 31, 2020	10,971,231
Beginning balance at Dec. 31, 2020	$ 349,789
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of Series A Preferred Shares at $56.66, net of issuance costs (in shares)	52,947
Issuance of Series A Preferred Shares at $56.66, net of issuance costs	$ 2,940
Ending balance (in shares) at Mar. 31, 2021	11,024,178
Ending balance at Mar. 31, 2021	$ 352,729
Beginning balance (in shares) at Dec. 31, 2020			20,477,338
Beginning balance at Dec. 31, 2020	(98,070)	$ (132,843)	$ 0	$ 31,132	$ (40)	$ (163,935)	$ 34,773
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	1,674	1,674		1,674
Warrants issued in license agreement	9,415						9,415
Net Loss	(61,565)	(61,565)				(61,565)
Comprehensive Income (Loss)	8	8			8
Ending balance (in shares) at Mar. 31, 2021			20,477,338
Ending balance at Mar. 31, 2021	$ (148,538)	(192,726)	$ 0	32,806	(32)	(225,500)	44,188
Beginning balance (in shares) at Dec. 31, 2020	10,971,231
Beginning balance at Dec. 31, 2020	$ 349,789
Ending balance (in shares) at Sep. 30, 2021	11,024,178
Ending balance at Sep. 30, 2021	$ 352,729
Beginning balance (in shares) at Dec. 31, 2020			20,477,338
Beginning balance at Dec. 31, 2020	(98,070)	(132,843)	$ 0	31,132	(40)	(163,935)	34,773
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Loss	(175,105)
Ending balance (in shares) at Sep. 30, 2021			21,787,245
Ending balance at Sep. 30, 2021	$ (253,062)	(297,250)	$ 0	41,726	64	(339,040)	44,188
Beginning balance (in shares) at Mar. 31, 2021	11,024,178
Beginning balance at Mar. 31, 2021	$ 352,729
Ending balance (in shares) at Jun. 30, 2021	11,024,178
Ending balance at Jun. 30, 2021	$ 352,729
Beginning balance (in shares) at Mar. 31, 2021			20,477,338
Beginning balance at Mar. 31, 2021	(148,538)	(192,726)	$ 0	32,806	(32)	(225,500)	44,188
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	1,443	1,443		1,443
Net Loss	(100,428)	(100,428)				(100,428)
Comprehensive Income (Loss)	122	122			122
Ending balance (in shares) at Jun. 30, 2021			20,477,338
Ending balance at Jun. 30, 2021	$ (247,401)	(291,589)	$ 0	34,249	90	(325,928)	44,188
Ending balance (in shares) at Sep. 30, 2021	11,024,178
Ending balance at Sep. 30, 2021	$ 352,729
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	2,168	2,168		2,168
Exercise of options (in shares)			1,309,907
Exercise of options	5,309	5,309		5,309
Net Loss	(13,112)	(13,112)				(13,112)
Comprehensive Income (Loss)	(26)	(26)			(26)
Ending balance (in shares) at Sep. 30, 2021			21,787,245
Ending balance at Sep. 30, 2021	$ (253,062)	(297,250)	$ 0	41,726	64	(339,040)	44,188
Beginning balance (in shares) at Dec. 31, 2021	0
Beginning balance at Dec. 31, 2021	$ 0
Ending balance (in shares) at Mar. 31, 2022	0
Ending balance at Mar. 31, 2022	$ 0
Beginning balance (in shares) at Dec. 31, 2021			107,275,458
Beginning balance at Dec. 31, 2021	387,336	353,562	$ 2	713,269	526	(360,235)	33,774
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	4,669	4,669		4,669
Receivable from related party	1,710	1,710		1,710
Net Loss	(27,726)	(27,726)				(27,726)
Comprehensive Income (Loss)	(1,216)	(1,216)			(1,216)
Ending balance (in shares) at Mar. 31, 2022			107,275,458
Ending balance at Mar. 31, 2022	$ 364,773	330,999	$ 2	719,648	(690)	(387,961)	33,774
Beginning balance (in shares) at Dec. 31, 2021	0
Beginning balance at Dec. 31, 2021	$ 0
Ending balance (in shares) at Sep. 30, 2022	0
Ending balance at Sep. 30, 2022	$ 0
Beginning balance (in shares) at Dec. 31, 2021			107,275,458
Beginning balance at Dec. 31, 2021	387,336	353,562	$ 2	713,269	526	(360,235)	33,774
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Loss	(92,014)
Ending balance (in shares) at Sep. 30, 2022			108,353,831
Ending balance at Sep. 30, 2022	$ 306,598	272,824	$ 2	728,915	(3,844)	(452,249)	33,774
Beginning balance (in shares) at Mar. 31, 2022	0
Beginning balance at Mar. 31, 2022	$ 0
Ending balance (in shares) at Jun. 30, 2022	0
Ending balance at Jun. 30, 2022	$ 0
Beginning balance (in shares) at Mar. 31, 2022			107,275,458
Beginning balance at Mar. 31, 2022	364,773	330,999	$ 2	719,648	(690)	(387,961)	33,774
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	4,528	4,528		4,528
Exercise of options (in shares)			1,000,000
Exercise of warrants (in shares)			78,373
Net Loss	(42,391)	(42,391)				(42,391)
Comprehensive Income (Loss)	(712)	(712)			(712)
Ending balance (in shares) at Jun. 30, 2022			108,353,831
Ending balance at Jun. 30, 2022	$ 326,198	292,424	$ 2	724,176	(1,402)	(430,352)	33,774
Ending balance (in shares) at Sep. 30, 2022	0
Ending balance at Sep. 30, 2022	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	4,739	4,739		4,739
Net Loss	(21,897)	(21,897)				(21,897)
Comprehensive Income (Loss)	(2,442)	(2,442)			(2,442)
Ending balance (in shares) at Sep. 30, 2022			108,353,831
Ending balance at Sep. 30, 2022	$ 306,598	$ 272,824	$ 2	$ 728,915	$ (3,844)	$ (452,249)	$ 33,774